NEO - NeoGenomics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
21.16
-1.42 (-6.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close22.58
Open22.60
Bid0.00 x 1800
Ask0.00 x 1100
Day's Range21.13 - 22.70
52 Week Range11.05 - 24.84
Volume1,394,288
Avg. Volume923,929
Market Cap2.165B
Beta (3Y Monthly)0.76
PE Ratio (TTM)335.87
EPS (TTM)0.06
Earnings DateJul 22, 2019 - Jul 26, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.00
Trade prices are not sourced from all markets
  • Did Hedge Funds Drop The Ball On NeoGenomics, Inc. (NEO) ?
    Insider Monkey4 days ago

    Did Hedge Funds Drop The Ball On NeoGenomics, Inc. (NEO) ?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Neogenomics Inc.

    Neogenomics Inc NASDAQ:NEOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for NEO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NEO are favorable, with net inflows of $1.27 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • ACCESSWIRE28 days ago

    NeoGenomics To Present At 39th Annual William Blair Growth Stock Conference

    FT. MYERS, FL / ACCESSWIRE / May 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive ...

  • ACCESSWIRElast month

    NeoGenomics and QIAGEN Collaborate to Offer Companion Diagnostic Test for HR+/HER2 - Advanced Breast Cancer Patients to Detect a PIK3CA Mutation

    FT. MYERS, FL / ACCESSWIRE / May 28, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced availability of the QIAGEN therascreen® PIK3CA ...

  • ACCESSWIRElast month

    NeoGenomics To Attend The 16th Annual Craig-Hallum Institutional Investor Conference

    FT. MYERS, FL / ACCESWIRE / May 23, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chief Executive Officer, Sharon ...

  • ACCESSWIRElast month

    NeoGenomics Announces Pricing on Public Offering of Common Stock

    MYERS, FL / ACCESSWIRE / May 21, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $21.25 per share. Gross proceeds to NeoGenomics from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by NeoGenomics, are expected to be $148,750,000. All shares of common stock to be sold in the offering are being sold by NeoGenomics.

  • Dow Jones Futures Signal Stock Market Rally As China Trade War Tensions Ease
    Investor's Business Dailylast month

    Dow Jones Futures Signal Stock Market Rally As China Trade War Tensions Ease

    Stock futures signaled solid market gains as the U.S. eased Huawei curbs. On Monday those curbs triggered a big sell-off in chip stocks like Broadcom and sent the Nasdaq tumbling.

  • ACCESSWIRElast month

    NeoGenomics Announces Proposed Public Offering of Common Stock

    MYERS, FL / ACCESSWIRE / May 20, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, announced today that it has commenced an underwritten public offering of approximately $150,000,000 of newly issued shares of common stock. All shares of common stock to be sold in the offering are being sold by NeoGenomics. In addition, NeoGenomics expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock at the public offering price, less underwriting discounts and commissions.

  • Are NeoGenomics, Inc.'s (NASDAQ:NEO) Interest Costs Too High?
    Simply Wall St.2 months ago

    Are NeoGenomics, Inc.'s (NASDAQ:NEO) Interest Costs Too High?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! NeoGenomics, Inc. (NASDAQ:NEO) is a small-cap stock with a market capitalization of US$2.2b. While in...

  • NeoGenomics (NEO) Hits Fresh High: Is There Still Room to Run?
    Zacks2 months ago

    NeoGenomics (NEO) Hits Fresh High: Is There Still Room to Run?

    NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Hedge Funds Have Never Been This Bullish On NeoGenomics, Inc. (NEO)
    Insider Monkey2 months ago

    Hedge Funds Have Never Been This Bullish On NeoGenomics, Inc. (NEO)

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of NEO earnings conference call or presentation 30-Apr-19 12:30pm GMT

    Q1 2019 Neogenomics Inc Earnings Call

  • Neogenomics Inc (NEO) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Neogenomics Inc (NEO) Q1 2019 Earnings Call Transcript

    NEO earnings call for the period ending March 31, 2019.

  • NeoGenomics (NEO) Tops Q1 Earnings and Revenue Estimates
    Zacks2 months ago

    NeoGenomics (NEO) Tops Q1 Earnings and Revenue Estimates

    NeoGenomics (NEO) delivered earnings and revenue surprises of 40.00% and 9.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    NeoGenomics: 1Q Earnings Snapshot

    The Fort Myers, Florida-based company said it had a loss of 3 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, came to 7 cents per share. The results exceeded Wall Street ...

  • ACCESSWIRE2 months ago

    NeoGenomics Reports 51% Revenue Growth to Record $96 Million in the First Quarter

    FT. MYERS, F L / ACCESSWIRE / April 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2019. ...

  • NeoGenomics (NEO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks2 months ago

    NeoGenomics (NEO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ACCESSWIRE3 months ago

    NeoGenomics Schedules its First Quarter Earnings Release for April 30, 2019

    MYERS, FL / ACCESSWIRE / April 3, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its first quarter 2019 financial results on Tuesday, April 30, 2019. The Company has scheduled a web-cast and conference call to discuss their first quarter results on Tuesday, April 30, 2019 at 8:30 AM EDT. NeoGenomics, Inc. specializes in cancer genetics testing and information services.

  • ACCESSWIRE3 months ago

    NeoGenomics to Present at 18th Annual Needham & Company Health Care Conference

    FT. MYERS, FLORIDA / ACCESSWIRE / April 2, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Sharon Virag, Chief Financial Officer, ...

  • GlobeNewswire3 months ago

    Report: Developing Opportunities within Carter's, Ingredion, NeoGenomics, American Financial Group, Inogen, and Forrester Research — Future Expectations, Projections Moving into 2019

    NEW YORK, March 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.